News

Under the collaboration, SIRS-Lab will provide access to selected biomarkers for sepsis. Biosite will then make antibodies to those selected targets using the company’s proprietary antibody development process,

The study will be conducted at the European Pancreas Center of the University of Heidelberg Clinic for Surgery. Enrolment will include up to 43 patients with advanced, inoperable

The FDA approval to expand to the final phase of the clinical trial was based on Refocus Group’s submission of preliminary data from phase II surgeries through mid-July

There are concerns that a strain of the H5N1 virus, which infects poultry, could be carried west by migrating wild birds. The virus, which is thought to have

The randomized, double-blind trial will compare the efficacy and safety of Alinia to that of a placebo. Alinia will be administered orally as a single 500 mg tablet

The heart defect being studied is known as Patent Foramen Ovale (PFO), a structural defect where a small hole between the right and left atria (upper chambers of

“The significance of this joint venture is that it now links a low-cost producer, with a huge manufacturing capacity,” Said Dr Frank Leung, Coremed’s founder. “Combined, this will

EndoTAG-1 is a combination of paclitaxel (sold as Taxol by Bristol-Myers Squibb) and a unique carrier system which targets paclitaxel to newly formed blood vessels. EndoTAG aims at

During the collaboration the researchers will combine Ciphergen’s biomarker discovery and diagnostic process with the university’s clinical expertise. As part of the collaboration, Ciphergen receives exclusive rights to